Targeting PELP1 oncogenic signaling in TNBC with the small molecule inhibitor SMIP34

PURPOSE: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Oncogenic PELP1 is frequently overexpressed in TNBC, and it has been demonstrated that PELP1 signaling is essential for TNBC progression. The therapeutic utility of targeting PELP1 in TNBC, however, remain...

Descripción completa

Detalles Bibliográficos
Autores principales: Altwegg, Kristin A., Pratap, Uday P., Liu, Zexuan, Liu, Junhao, Sanchez, John R., Yang, Xue, Ebrahimi, Behnam, Panneerdoss, Durga Meenakshi, Li, Xiaonan, Sareddy, Gangadhara R., Viswanadhapalli, Suryavathi, Rao, Manjeet K., Vadlamudi, Ratna K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Original Laboratory Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224866/
https://www.ncbi.nlm.nih.gov/pubmed/37199805
http://dx.doi.org/10.1007/s10549-023-06958-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224866/
https://www.ncbi.nlm.nih.gov/pubmed/37199805
http://dx.doi.org/10.1007/s10549-023-06958-4

Ejemplares similares